Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 1415 | 26.365 |
09:34 ET | 2100 | 26.395 |
09:36 ET | 221 | 26.405 |
09:39 ET | 300 | 26.7 |
09:41 ET | 100 | 26.5625 |
09:43 ET | 200 | 26.66 |
09:45 ET | 550 | 26.57 |
09:48 ET | 700 | 26.45 |
09:50 ET | 2700 | 26.41 |
09:52 ET | 100 | 26.5 |
09:54 ET | 200 | 26.37 |
09:56 ET | 300 | 26.37 |
09:57 ET | 400 | 26.49 |
09:59 ET | 501 | 26.5 |
10:01 ET | 100 | 26.555 |
10:03 ET | 1751 | 26.42 |
10:06 ET | 539 | 26.33 |
10:08 ET | 700 | 26.1975 |
10:10 ET | 542 | 26.33 |
10:14 ET | 500 | 26.06 |
10:15 ET | 100 | 26.04 |
10:17 ET | 723 | 25.95 |
10:19 ET | 188 | 26.02 |
10:24 ET | 111 | 25.9932 |
10:28 ET | 100 | 26.09 |
10:32 ET | 100 | 26.035 |
10:37 ET | 896 | 26.1 |
10:39 ET | 600 | 26.105 |
10:44 ET | 300 | 26.24 |
10:46 ET | 1000 | 26.2 |
10:50 ET | 100 | 26.26 |
10:53 ET | 300 | 26.24 |
11:00 ET | 100 | 26.25 |
11:09 ET | 100 | 26.28 |
11:20 ET | 764 | 26.28 |
11:22 ET | 200 | 26.33 |
11:26 ET | 1507 | 26.315 |
11:27 ET | 400 | 26.42 |
11:29 ET | 200 | 26.42 |
11:31 ET | 100 | 26.49 |
11:33 ET | 1505 | 26.36 |
11:36 ET | 200 | 26.395 |
11:42 ET | 1083 | 26.3 |
11:44 ET | 1481 | 26.31 |
11:45 ET | 100 | 26.19 |
11:49 ET | 100 | 26.19 |
11:54 ET | 100 | 26.13 |
11:58 ET | 905 | 26.19 |
12:05 ET | 424 | 26.12 |
12:14 ET | 100 | 26.14 |
12:16 ET | 200 | 26.14 |
12:18 ET | 100 | 26.11 |
12:20 ET | 200 | 26.12 |
12:23 ET | 600 | 26.125 |
12:30 ET | 200 | 26.12 |
12:32 ET | 304 | 26.13 |
12:36 ET | 1000 | 26.11 |
12:41 ET | 100 | 26.17 |
12:45 ET | 442 | 26.19 |
12:48 ET | 134 | 26.1201 |
12:52 ET | 500 | 26.155 |
12:56 ET | 100 | 26.125 |
12:57 ET | 764 | 26.1389 |
01:03 ET | 100 | 26.15 |
01:08 ET | 600 | 26.15 |
01:12 ET | 200 | 26.12 |
01:15 ET | 100 | 26.11 |
01:19 ET | 300 | 26.09 |
01:21 ET | 310 | 26.135 |
01:26 ET | 100 | 26.15 |
01:28 ET | 500 | 26.18 |
01:30 ET | 1015 | 26.2 |
01:33 ET | 652 | 26.26 |
01:35 ET | 100 | 26.28 |
01:39 ET | 125 | 26.37 |
01:44 ET | 315 | 26.31 |
01:46 ET | 400 | 26.28 |
01:48 ET | 200 | 26.35 |
01:50 ET | 200 | 26.31 |
01:51 ET | 769 | 26.31 |
01:55 ET | 100 | 26.34 |
01:57 ET | 200 | 26.33 |
02:00 ET | 600 | 26.285 |
02:02 ET | 400 | 26.3 |
02:04 ET | 100 | 26.32 |
02:06 ET | 100 | 26.34 |
02:08 ET | 100 | 26.325 |
02:09 ET | 1100 | 26.3 |
02:13 ET | 100 | 26.29 |
02:15 ET | 700 | 26.27 |
02:20 ET | 100 | 26.22 |
02:22 ET | 200 | 26.25 |
02:26 ET | 100 | 26.27 |
02:27 ET | 300 | 26.28 |
02:31 ET | 278 | 26.3 |
02:36 ET | 100 | 26.34 |
02:38 ET | 500 | 26.28 |
02:40 ET | 100 | 26.28 |
02:44 ET | 600 | 26.19 |
02:49 ET | 100 | 26.1425 |
02:54 ET | 2600 | 26.1 |
02:56 ET | 200 | 26.15 |
02:58 ET | 100 | 26.11 |
03:02 ET | 300 | 26.15 |
03:03 ET | 100 | 26.08 |
03:09 ET | 549 | 26.08 |
03:12 ET | 2300 | 26.14 |
03:18 ET | 200 | 26.14 |
03:20 ET | 816 | 26.13 |
03:23 ET | 3512 | 26.21 |
03:25 ET | 100 | 26.1601 |
03:30 ET | 800 | 26.205 |
03:32 ET | 1500 | 26.2599 |
03:34 ET | 200 | 26.26 |
03:36 ET | 130 | 26.3 |
03:38 ET | 100 | 26.33 |
03:39 ET | 1200 | 26.33 |
03:43 ET | 282 | 26.335 |
03:45 ET | 500 | 26.325 |
03:48 ET | 3300 | 26.27 |
03:50 ET | 513 | 26.3 |
03:52 ET | 300 | 26.33 |
03:54 ET | 900 | 26.32 |
03:56 ET | 2574 | 26.37 |
03:57 ET | 3540 | 26.35 |
03:59 ET | 52218 | 26.43 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.9B | -147.8x | --- |
CareDx Inc | 1.8B | -11.1x | --- |
Zai Lab Ltd | 1.7B | -5.7x | --- |
Maravai LifeSciences Holdings Inc | 2.2B | -8.8x | --- |
Galapagos NV | 1.7B | 47.3x | --- |
BioCryst Pharmaceuticals Inc | 1.7B | -11.0x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9B |
---|---|
Revenue (TTM) | $338.9M |
Shares Outstanding | 71.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.32 |
EPS | $-0.18 |
Book Value | $6.23 |
P/E Ratio | -147.8x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.